Low- versus high-dose nafamostat for anticoagulation during CRRT in ICU patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, randomized, open-label trial will enroll adult ICU patients at Zhujiang Hospital who require CRRT for at least 24 hours and meet predefined coagulation and laboratory criteria. Participants are randomized to continuous pre-filter infusion of nafamostat mesilate at an initial dose of 20 mg/h (low-dose) or 50 mg/h (high-dose), with dose adjustments as needed to maintain target anticoagulation. The primary outcome is filter lifespan, and secondary outcomes include transmembrane pressure, circuit clotting events, delivered dialysis dose, CRRT duration, and safety outcomes such as bleeding and adverse drug reactions. Key exclusions include active bleeding, known nafamostat allergy, concurrent systemic anticoagulants or extracorporeal devices, pregnancy, and BMI or lab values outside specified ranges.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \& Gender: Aged 18 to 80 years, regardless of gender.
2. Clinical Indication: Admitted to the Intensive Care Unit (ICU) with a confirmed indication for Continuous Renal Replacement Therapy (CRRT) and an expected treatment duration of greater than 24 hours.
3. Coagulation Status: Normal coagulation function prior to CRRT initiation, defined as:International Normalized Ratio (INR) ≤ 1.5,Fibrinogen (FIB) ≥ 1.5 g/L,Activated Partial Thromboplastin Time (APTT) ≤ 45 seconds
4. Platelet Count: Platelet count (PLT) ≥ 50 × 10⁹/L.
5. Body Mass Index (BMI): 18.5 kg/m² ≤ BMI ≤ 25 kg/m².
6. Informed Consent: Written informed consent obtained from the patient or their legally authorized representative.

Exclusion Criteria:

1. Hypersensitivity: Known allergy or hypersensitivity to Nafamostat Mesilate or any component of the formulation.
2. Active Bleeding: Presence of active bleeding or a high risk of bleeding that contraindicates anticoagulation (e.g., active gastrointestinal bleeding, intracranial hemorrhage, or recent major surgery with a high bleeding risk).
3. Pregnancy/Lactation: Pregnant or breastfeeding women.
4. Concurrent Anticoagulation: Current use of other systemic anticoagulants (e.g., unfractionated heparin, low molecular weight heparin, warfarin, or direct oral anticoagulants) that cannot be discontinued.
5. Concurrent Extracorporeal Support: Concurrent use of other extracorporeal life support or blood purification therapies that may interfere with coagulation assessment, such as Extracorporeal Membrane Oxygenation (ECMO), Intra-Aortic Balloon Pump (IABP), or Plasma Exchange (PE).
6. Severe Liver Dysfunction: Severe hepatic impairment (Child-Pugh Class C) or baseline total bilirubin levels exceeding 5 times the upper limit of normal.
7. Limited Life Expectancy: Expected survival time of less than 24 hours due to the progression of underlying disease.
8. Conflicting Trials: Current participation in another interventional clinical trial that may influence the outcomes of this study.

Where it's running

• Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Zhanguo Liu, M.D.PhD — Department of Critical Care Medicine of Zhujiang Hospital
• Study coordinator: Zhanguo Liu, M.D.PhD
• Email: zhguoliu@163.com
• Phone: +86-2062782927

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levetiracetam Dosing in Critically Ill on CRRT

  This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.

  Recruiting Chulalongkorn University · Pathum Wan, Bangkok · NCT07918833

• High vs standard protein intake in critically ill adults with acute kidney injury on CRRT

  This study tests whether a higher protein diet helps adult ICU patients with acute kidney injury who are receiving continuous renal replacement therapy.

  Recruiting Chulalongkorn University · Bangkok, Bangkok · NCT07596043

• Citrate anticoagulation protocol to stabilize electrolytes during continuous renal replacement in ICU adults

  This test tries to see if a modified CRRT method using citrate anticoagulation with post-filter replacement keeps electrolytes more stable and reduces the need for supplements in adult ICU patients with acute kidney injury.

  Recruiting Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona, Barcelona · NCT07514650

• Fluid balance guided by mVExUS in ICU patients on CRRT with acute kidney injury

  This trial tests whether using modified venous excess ultrasound (mVExUS) to guide fluid removal in ICU patients on CRRT with AKI can achieve a better fluid balance in the first 72 hours compared with standard care.

  Recruiting Chulalongkorn University · Bangkok and 1 other locations · NCT07346118

• Evaluating the safety of Prismocitrate 18 for patients on continuous renal replacement therapy

  This study is testing if a new solution called Prismocitrate 18 is safe for patients on a special type of kidney treatment to help prevent blood clots during their therapy.

  Recruiting at 7 sites Phase 3 Vantive Health LLC · Birmingham, Alabama and 13 other locations · NCT05399537

• Intra-Abdominal Pressure Changes During CRRT in Critically Ill Adults

  This study tests how intra-abdominal pressure changes in critically ill adults on continuous renal replacement therapy using a bladder pressure measurement.

  Recruiting Bursa Yuksek Ihtisas Training and Research Hospital · Bursa, Bursa · NCT07823387

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.